Home/Filings/4/0001209191-23-016023
4//SEC Filing

Henderson Molly 4

Accession 0001209191-23-016023

CIK 0001783183other

Filed

Mar 2, 7:00 PM ET

Accepted

Mar 3, 7:03 PM ET

Size

6.1 KB

Accession

0001209191-23-016023

Insider Transaction Report

Form 4
Period: 2023-03-01
Henderson Molly
CFO and CBO
Transactions
  • Sale

    Common Stock

    2023-03-01$8.53/sh2,032$17,33576,015 total
Holdings
  • Common Stock

    (indirect: By 401(k))
    338.86
Footnotes (2)
  • [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.
  • [F2]Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.3385 to $8.5524. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Phathom Pharmaceuticals, Inc.

CIK 0001783183

Entity typeother

Related Parties

1
  • filerCIK 0001363812

Filing Metadata

Form type
4
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 7:03 PM ET
Size
6.1 KB